These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9327252)

  • 1. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the Etest.
    Schrock J; Hackman BA; Plouffe JF
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):221-3. PubMed ID: 9327252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
    Stout JE; Sens K; Mietzner S; Obman A; Yu VL
    Int J Antimicrob Agents; 2005 Apr; 25(4):302-7. PubMed ID: 15784309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells.
    Stout JE; Arnold B; Yu VL
    Diagn Microbiol Infect Dis; 1998 Jan; 30(1):37-43. PubMed ID: 9488830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility study of BMS-284756 against Legionella species.
    Dubois J; St-Pierre C
    Diagn Microbiol Infect Dis; 2001; 41(1-2):79-82. PubMed ID: 11687318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1999 Jan; 43(1):90-5. PubMed ID: 9869571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibility testing of clinical strains of Legionella spp. isolated in Japan].
    Murakami H; Matsumoto T; Kobayashi T; Isogai K; Kashitani F; Furuya N; Tateda K; Yamaguchi K
    Kansenshogaku Zasshi; 2001 Jan; 75(1):1-6. PubMed ID: 11218381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic susceptibility of environmental
    Sreenath K; Chaudhry R; Vinayaraj EV; Thakur B
    Future Microbiol; 2019 May; 14():661-669. PubMed ID: 31148475
    [No Abstract]   [Full Text] [Related]  

  • 8. Minimum inhibitory concentration (MIC) distribution among wild-type strains of Legionella pneumophila identifies a subpopulation with reduced susceptibility to macrolides owing to efflux pump genes.
    Vandewalle-Capo M; Massip C; Descours G; Charavit J; Chastang J; Billy PA; Boisset S; Lina G; Gilbert C; Maurin M; Jarraud S; Ginevra C
    Int J Antimicrob Agents; 2017 Nov; 50(5):684-689. PubMed ID: 28782709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.
    Martin SJ; Pendland SL; Chen C; Schreckenberger P; Danziger LH
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1419-21. PubMed ID: 8726012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Legionnaires' disease].
    Koide M; Saito A
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():438-42. PubMed ID: 12722258
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimicrobial susceptibility of Legionella pneumophila Serogroups I--IV.
    Saravolatz LD; Pohlod DJ; Quinn EL
    Scand J Infect Dis; 1980; 12(3):215-9. PubMed ID: 7433921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of severe respiratory infection. Legionella pneumonia].
    Saito A
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):281-5. PubMed ID: 2615084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis, diagnosis and therapy of Legionella infections].
    Lück PC; Steinert M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 May; 49(5):439-49. PubMed ID: 16596363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal.
    Minetti C; Barton R; Farley C; Spiller OB; Rodrigues R; Gonçalves P
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1297-1308. PubMed ID: 38696083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia.
    Miyashita N; Higa F; Aoki Y; Kikuchi T; Seki M; Tateda K; Maki N; Uchino K; Ogasawara K; Kiyota H; Watanabe A
    J Infect Chemother; 2020 May; 26(5):411-417. PubMed ID: 32081644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides.
    Samra Z; Rosenberg S; Soffer Y
    Diagn Microbiol Infect Dis; 2002 Dec; 44(4):359-61. PubMed ID: 12543541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of macrolides against intracellular Legionella pneumophila.
    Segreti J; Meyer P; Kapell K
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legionella: macrolides or quinolones?
    Pedro-Botet L; Yu VL
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():25-30. PubMed ID: 16669926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J; St-Pierre C
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.